REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

AP Biosciences Inc (圆祥生技股份有限公司) (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: AP Biosciences Inc Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English & Chinese Download a sample report

AP Biosciences, Inc. is a clinical-stage bispecific antibody new drug research and development company. The company's main products are a series of antibody and protein lead drugs. The company was established in 2013 and is headquartered in Taipei City, Taiwan.

Headquarters
11F-2,No508,Sec7,Zhongxao E Rd
Taipei City; Taipei City;

Contact Details: Purchase the AP Biosciences Inc (圆祥生技股份有限公司) report to view the information.

Website: http://www.apbioinc.com

Basic Information
Total Employees:
Purchase the AP Biosciences Inc (圆祥生技股份有限公司) report to view the information.
Outstanding Shares:
Purchase the AP Biosciences Inc (圆祥生技股份有限公司) report to view the information.
Financial Auditors:
Purchase the AP Biosciences Inc (圆祥生技股份有限公司) report to view the information.
Incorporation Date:
May 27, 2013
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
35.87%
Purchase this report to view the information.
3.09%
Purchase this report to view the information.
1%
Purchase this report to view the information.
Purchase this report to view the information.
Subsidiaries
Apbio Pty Ltd (Australia)
100%
Company Performance
Financial values in the chart are available after AP Biosciences Inc (圆祥生技股份有限公司) report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Total operating revenue
-34.18%▼
Operating profit (EBIT)
14.88%▲
EBITDA
17.06%▲
Net Profit (Loss) for the Period
12.62%▲
Total Assets
-18.06%▼
Total Equity
-18.22%▼
Return on Equity (ROE)
-0.87%▼
Debt/Equity
0.18%▲
Quick Ratio
-4.41%▼
Cash Ratio
-1.96%▼

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo